Evan David Seigerman
Stock Analyst at BMO Capital
(0.88)
# 2122
Out of 5,331 analysts
44
Total ratings
30.30%
Success rate
9.36%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceut... | Maintains: Outperform | 865 800 | 604.66 | 32.31% | 6 | Apr 30, 2025 | |
NVO Novo Nordisk | Downgrades: Market Perform | 105 64 | 69.22 | -7.54% | 6 | Apr 17, 2025 | |
MRK Merck & Co | Maintains: Market Perform | 105 96 | 83.05 | 15.59% | 4 | Feb 5, 2025 | |
ABBV AbbVie | Maintains: Outperform | 208 215 | 198.44 | 8.35% | 7 | Feb 3, 2025 | |
REPL Replimune Group | Maintains: Outperform | 18 27 | 10.03 | 169.19% | 3 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 52 57 | n/a | n/a | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 83 100 | 27.09 | 269.14% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 336 355 | 280.93 | 26.37% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 33 36 | 24.19 | 48.82% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 31 72 | n/a | n/a | 4 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 9 3 | 5.27 | -43.07% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 369 396 | 824.15 | -51.95% | 1 | Sep 6, 2022 |